| Name | Title | Contact Details |
|---|
Tango2 is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Optivus is a San Bernardino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Omnica Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clay County Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Clay Center, KS. To find more information about Clay County Medical Center, please visit www.ccmcks.org
MRI Interventions, Inc. is a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Since our inception in 1998, we have focused on research and product development in the field of interventional MRI. From 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling MRI-guided interventions and to build an intellectual property position. In 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. We have two product platforms. Our ClearPoint® system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. Our ClearTrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. Both systems utilize intra-procedural magnetic resonance imaging to guide the procedures. Both systems are designed to work in a hospital’s existing MRI suite. Our products are designed to provide a new, minimally invasive surgical approach for the benefit of large patient populations. Our ClearPoint system is designed to enable the delivery of therapies to treat certain neurological diseases. Our ClearTrace system is designed to deliver therapies to treat certain cardiac diseases. We believe that our two product platforms, subject to appropriate regulatory clearance and approval, will provide better patient outcomes, enable physicians and hospitals to treat more patients, and reduce costs to the healthcare system.